Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

28.51
-1.2700-4.26%
Volume:813.21K
Turnover:23.31M
Market Cap:2.26B
PE:-9.96
High:29.69
Open:29.42
Low:28.01
Close:29.78
52wk High:47.65
52wk Low:8.24
Shares:79.14M
Float Shares:55.73M
Volume Ratio:0.77
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8636
EPS(LYR):-3.6632
ROE:-42.14%
ROA:-26.50%
PB:3.91
PE(LYR):-7.78

Loading ...

Mineralys Therapeutics Grants Inducement Equity Awards to New Employees

Reuters
·
Yesterday

Press Release: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Yesterday

Chief Medical Officer David Malcom Rodman Sells Common Shares of Mineralys Therapeutics Inc

Reuters
·
Yesterday

Mineralys Therapeutics Inc call volume above normal and directionally bullish

TIPRANKS
·
Jan 24

Chief Medical Officer David Malcom Rodman Reports Sale of Mineralys Therapeutics Inc. Common Shares

Reuters
·
Jan 21

Mineralys Therapeutics (MLYS) Valuation After Q3 Beat And Lorundrostat NDA Progress

Simply Wall St.
·
Jan 19

Mineralys Therapeutics CEO Jon Congleton Reports Disposal of Common Shares

Reuters
·
Jan 14

CFO Adam Scott Levy Sells Common Shares of Mineralys Therapeutics Inc

Reuters
·
Jan 14

Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch

TIPRANKS
·
Jan 14

Mineralys Therapeutics Inc - Filed Nda for Lorundrostat to U.S. FDA in Late 2025

THOMSON REUTERS
·
Jan 06

Mineralys Therapeutics Inc - Co Remains on Track to Report Topline Results From Phase 2 Explore-Osa Trial in Q1 2026

THOMSON REUTERS
·
Jan 06

Mineralys Therapeutics Submits NDA for Lorundrostat to FDA

Reuters
·
Jan 06

Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative?

Simply Wall St.
·
Dec 21, 2025

Mineralys Therapeutics Inc : Bofa Global Research Raises Price Objective to $46 From $43

THOMSON REUTERS
·
Dec 19, 2025

How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing

Simply Wall St.
·
Dec 01, 2025

BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 27, 2025

Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares

Reuters
·
Nov 22, 2025

Mineralys Therapeutics Q3 EPS USD -0.52

Reuters
·
Nov 20, 2025

Mineralys Therapeutics Shares Fall Following Executives' Stock Sale

MT Newswires Live
·
Nov 15, 2025

Mineralys Therapeutics falls -13.9%

TIPRANKS
·
Nov 14, 2025